Johnson & Johnson Returns 58% on Slower Growth Than Eli Lilly
JNJ returned 58% in twelve months, beating Eli Lilly's 54% despite growing revenue at 8.1% versus Lilly's 49.6%. The rally is a bet on life after STELARA.
Topic
Pharmaceuticals
Topic
Topic
Topic
JNJ returned 58% in twelve months, beating Eli Lilly's 54% despite growing revenue at 8.1% versus Lilly's 49.6%. The rally is a bet on life after STELARA.